

Protect Bioidentical Hormones!

Millions of patients are at risk of losing access to compounded bioidentical hormones, including estriol, progesterone, and testosterone.

What is the threat?

Bioidentical hormones have been nominated to the FDA's Difficult to Compound List, and items on this list when it is completed will no longer be able to be made at compounding pharmacies. Several bioidentical hormones (estriol, estradiol, progesterone, and testosterone) have been nominated to the list.

FDA bias against bioidenticals

FDA tasked a National Academy of Science, Engineering, and Medicine (NASEM) committee to assess the "clinical utility" of compounded bioidentical hormones (cBHRT). The committee was appointed without representation from anyone who either compounds cBHRT or uses these treatments in a medical practice. Unsurprisingly this committee has concluded that cBHRT offers "no clinical utility" and poses a "public health threat" without citing any evidence of harm.

The door is now wide open for FDA to do what we've long assumed they would— eliminate YOUR access to bioidenticals. The agency has already accepted the committee's findings and stands poised to further this process.

We have not given up the fight. Won't you join us and stand up before it's too late.



alliance for
natural health
USA

www.anh-usa.org